Who's Calling the Shots? The Influence of Pharmaceutical Industry Advertising on Drug Use

Bombardier C Laine L Reicin A Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520–8.

Curfman G Morrissey S Drazen J . Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520–8. N Engl J Med 2005; 353:2813–14.

Macleans.ca. Studies suggest drug company used academic researchers to manipulate data. 16 April, 2008. Available: http://oncampus.macleans.ca/education/2008/04/16/studies-suggest-drug-company-used-academic-researchers-to-manipulate-data/ (accessed July 17, 2010).

DeAngelis CD Fontanarosa PB . Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008;299(15):1833–5.

Waxman HA . Statement of Rep. Henry A. Waxman for the Hearing, “The roles of FDA and pharmaceutical companies in ensuring the safety of approved drugs like Vioxx.” Congress of the United States. House of Representatives. Committee on Government Reform. Washington DC: May 5, 2005.

Graham DJ Campen D Hui R Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475–81.

Wazana A . Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283(3):373–80.

Mintzes B . Educational initiative for medical and pharmacy students about drug promotion: an international cross-sectional survey — EDM Research Series No. 036. Geneva: World Health Organization; 2005. Available: http://apps.who.int/medicinedocs/en/d/Js8110e/1.html#Js8110e.1 (accessed July 8, 2010).

Sierles FS Brodkey AC Cleary LM Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA 2005;294:1034–42.

McCormick BB Tomlinson G Brill-Edwards P Detsky AS . Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 2001;286(16):1994–9.

Wilson D . Harvard Medical School in ethics quandary. The New York Times. March 3, 2009. Available: www.nytimes.com/2009/03/03/business/03medschool.html?_r=1 (accessed October 31, 2009).

Chimonas S Brennan TA Rothman DJ . Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med 2007;22:184–90.

Steinman MA Shlipak MG McPhee SJ . Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110:551–7.

Chren MM . Interactions between physicians and drug company representatives. Am J Med 1999;107:182–3.

Dana J Loewenstein G . A social science perspective on gifts to physicians from industry. JAMA 2003;290(2):252–5.

Friedman H Herskovitz P . The effect of a gift-upon-entry on sales: reciprocity in a retailing context. Mid-American Journal of Business 1990;5:49.

Katz D Caplan A Merz J . All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift giving. Am J Bioethics 2003;3:39–46.

Campbell EG Gruen RL Mountford J A national survey of physician-industry relationships. N Engl J Med 2007;356(17):1742–50.

Huang FY Weiss DS Fenimore PG The association of pharmaceutical company promotional spending with resident physician prescribing behavior. Acad Psychiatry 2005;29(5):500–1.

Watkins C Moore L Harvey I Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ 2003;326:1178–9.

Chren MM Landefeld CS . Physicians' behavior and their interaction with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684–9.

Ubel PA Jepson C Asch DA . Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. J Gen Int Med 2003;18:977–83.

Ziegler MG Lew P Singer BC . The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995;273:1296–8.

Harris GA . Pfizer pays $2.3 billion to settle marketing case. The New York Times. September 2, 2009. Available: www.nytimes.com/2009/09/03/business/03health.html?_r=4&hp (accessed October 31, 2009).

Angell MA . Drug companies & doctors: a story of corruption. New York Times Review of Books 2009; January 15:56(1).

Harris GA Carey BE . Researchers fail to reveal full drug pay. The New York Times. June 8, 2008. Available: www.nytimes.com/2008/06/08/us/08conflict.html (accessed October 31, 2009).

TheBostonChannel.com. Mass doctors get big money from drug companies. September 24, 2009. Available: www.thebostonchannel.com/investigative/21106691/detail.html (accessed October 31, 2009).

Ross JS Hill KP Egilman DS Krumholz HM . Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299(15):1800–12.

Kravitz RL Epstein RM Feldman MD Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293(16):1995–2002.

Sellors J Kaczorowski J Sellors C A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003;169(1):17–22.